Technologically Processed Highly Diluted Antibodies to S100 Protein in the Treatment of Neurotic Disorders: The Review
| Autor: | Victoria Vyacheslavovna Fateeva, Kristina Konstantinovna Khacheva, Gulnara Rinatovna Khakimova, Alexey Borisovich Glazunov |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
biology
business.industry InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL S100 protein 030227 psychiatry 03 medical and health sciences 0302 clinical medicine Neurotic Disorders Immunology biology.protein Medicine Antibody business GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) 030217 neurology & neurosurgery |
| Popis: | Neurotic disorders (NDs) are among the most common mental diseases leading to a decrease in the quality of life, lack of socialization, and increased mortality. The diagnosis and treatment of all types of NDs are challenging. In the light of the ongoing search for an effective and safe therapeutic strategy influencing certain aspects of ND pathogenesis, technologically processed highly diluted antibodies to S100 protein (TP Abs to S100) seem to be a promising treatment option for patients with NDs. TP Abs to S100 possess stress-protective, anxiolytic, antidepressant, antiamnestic, and neuroprotective activities. In the current review, we describe the mechanisms of action and pharmacological effects of TP Abs to S100 demonstrated in nonclinical (preclinical) and clinical studies. Based on the data, we tried to evaluate the future prospects of the TP Abs to S100 as the drug of choice for ND treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|